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Summary
 
Leukotrienes are potent inflammatory mediators synthesized from arachidonic acid (AA) pre-
dominately by cells of myeloid origin. The synthesis of these lipids is believed to be dependent
not only on the expression of the enzyme 5-lipoxygenase (5-LO), which catalyzes the first steps
in the synthesis of leukotrienes, but also on expression of a nuclear membrane protein termed
the 5-LO–activating protein (FLAP). To study the relationship of these two proteins in medi-
ating the production of leukotrienes in vivo and to determine whether the membrane protein
FLAP has additional functions in various inflammatory processes, we have generated a mouse
line deficient in this protein. FLAP-deficient mice develop normally and are healthy. How-
ever, an array of assays comparing inflammatory reactions in FLAP-deficient mice and in nor-
mal controls revealed that FLAP plays a role in a subset of these reactions. Although examina-
tion of DTH and IgE-mediated passive anaphylaxis showed no difference between wild-type
and FLAP-deficient animals, mice without FLAP possessed a blunted inflammatory response to
topical AA and had increased resistance to platelet-activating factor–induced shock compared
to controls. Also, edema associated with Zymosan A–induced peritonitis was markedly reduced
in animals lacking FLAP. To determine whether these differences relate solely to a deficit in
leukotriene production, or whether they reflect an additional role for FLAP in inflammation,
we compared the FLAP-deficient mice to 5-LO–deficient animals. Evaluation of mice lacking
FLAP and 5-LO indicated that production of leukotrienes during inflammatory responses is
dependent upon the availability of FLAP and did not support additional functions for FLAP
beyond its role in leukotriene production.
 
L
 
eukotrienes are potent lipid mediators of inflammatory
responses and have been implicated in the pathophysi-
ology of both acute and chronic inflammatory diseases in-
cluding asthma, arthritis, psoriasis, and inflammatory bowel
disease (1–6). The first committed step in the production of
all leukotrienes from arachidonic acid (AA)
 
1
 
 is dependent
on the expression of arachidonate 5-lipoxygenase (5-LO).
AA is released from endogenous phospholipids in intact
cells, presumably by the action of cytosolic AA-specific phos-
pholipase A
 
2
 
 (7–9). 5-LO then catalyses a two-step process
involving oxygenation of AA to produce the intermediate
5-hydroperoxyeicosatetraenoic acid, followed by a dehy-
dration step to produce the epoxide intermediate leuko-
triene A
 
4
 
 (LTA
 
4
 
). LTA
 
4
 
 is either converted to leukotriene
B
 
4
 
 by the enzyme LTA
 
4
 
 hydrolase, or is conjugated with
glutathione to form the cysteinyl leukotriene compound
LTC
 
4
 
 (10, 11). LTB
 
4
 
, synthesized predominantly by neu-
trophils, interacts with high-affinity G protein–coupled re-
ceptors which mediate a number of leukocyte functions. In
particular, LTB
 
4
 
 has been shown to be a potent chemotac-
tic factor for neutrophils, to stimulate adhesion of leuko-
cytes to vascular endothelia for extravasation into adjacent
tissue, and to initiate neutrophil degranulation (12, 13).
The peptidyl leukotrienes include LTC
 
4
 
 and its metabolites
LTD
 
4
 
, and LTE
 
4
 
, which are also known as the slow-react-
ing substance of anaphylaxis. These leukotrienes are se-
creted by eosinophils, mast cells, and macrophages, and po-
tently stimulate bronchoconstriction and mucous secretion
and cause vasodilation with increases in postcapillary ven-
ule permeability (1, 14).
 
1
 
Abbreviations used in this paper:
 
 AA, arachidonic acid; DTH, delayed-type
hypersensitivity; EIA, enzyme immunoassay; ES, embryonic stem; FLAP,
5-lipoxygenase–activating protein; HETE, hydroxyeicosatetraenoic acid;
HSA, human serum albumin; LO, lipoxygenase; LT, leukotriene; MPO,
myeloperoxidase; 
 
neo
 
, neomysin resistance gene; PAF, platelet-activating
factor; PG, prostaglandin; TX, thromboxane.
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In resting myeloid cells, 5-LO is found in the cytoplasm
and the nucleus. When cells are stimulated to produce leu-
kotrienes, 5-LO becomes associated with the nuclear enve-
lope (15, 16). This translocation is believed to be related to
the association of the enzyme with a protein termed the
5-lipoxygenase–activating protein (FLAP), located in the
nuclear membrane. The gene encoding this 18-kD protein
has been cloned (17). Based on its deduced amino acid se-
quence, FLAP has been hypothesized to consist of three trans-
membrane spanning regions with COOH and NH
 
2
 
 ter-
mini on opposite sides of the membrane (18), and shows
homology (31% amino acid identity, 53% similarity) with
LTC
 
4
 
 synthase, the enzyme responsible for peptidyl leuko-
triene production (19). Recent pharmacological studies iden-
tifying a new 30-kD protein with properties similar to FLAP
confirm the existence of a FLAP/LTC
 
4
 
 synthase gene fam-
ily (20). The significance of this homology between the
two proteins, however, is unknown. In contrast to the 5-LO
enzyme, FLAP has been found to be associated with the
membrane fraction in both resting and activated cells, and
the protein has been localized to the cisternum of the nu-
clear envelope and to the associated endoplasmic reticulum
(21). After activation, phospholipase A
 
2
 
 appears to translocate
to the nuclear fraction along with cellular 5-LO (15). Sev-
eral lines of evidence have advanced a model for the initia-
tion of leukotriene synthesis in which FLAP plays a critical,
and perhaps essential, role in leukotriene production. This
evidence includes studies of leukotriene synthesis in cells
transfected with transgenes encoding 5-LO and FLAP (17), as
well as studies of leukotriene inhibitors such as MK-886,
which binds to FLAP and prevents 5-LO from metaboliz-
ing AA (22). These inhibitors can block leukotriene syn-
thesis in intact cells but do not affect the catalytic activities
of purified 5-LO. Current models suggest that FLAP is not
involved directly in the recruitment of 5-LO to the nuclear
envelope. Instead, by binding both AA and 5-LO, FLAP
produces, in effect, a high local concentration of the sub-
strate on which the enzyme can act (23).
Leukotrienes are synthesized primarily by cells of mye-
loid lineage. As predicted by the unique cooperation re-
quired between FLAP and 5-LO in leukotriene production,
 
Flap
 
 expression has been detected in all cells where 
 
5-lo
 
mRNA is present and leukotrienes are made. 
 
Flap
 
 expres-
sion is highest in neutrophils, but is also present in signifi-
cant quantities in mast cells, eosinophils, and monocyte/
macrophages (15, 22, 24–26). Quantitative comparison of
 
Flap
 
 mRNA in these cell types is complicated by the fact that
each has been determined in different experiments by dif-
ferent investigators. 
 
Flap
 
 and 
 
5-lo
 
 messages have also been
detected at lower levels in B cell lines (24, 27–29) and in
extrahematopoietic cells types including keratinocytes (30,
31), colonic epithelia (32), and pancreas (33). The cloning
of the 
 
Flap
 
 and 
 
5-lo
 
 genes, however, has shown that their
promoters do not appear to share similar control elements,
which is surprising considering the unique relationship of
the two proteins (34, 35). The independent regulation of
these genes is further supported by the different expression
patterns of 
 
5-lo
 
 and 
 
Flap
 
 in a subset of cell types and under
different stimuli (27, 35). 
 
Flap
 
 expression in the absence of
 
5-lo
 
 has been observed in several T cells lines (8, 28, 29), in
the Mono Mac 6 cell line, and in U-937 cells (29). This fact,
along with its unusual cellular location and high levels of
expression, has led to speculation that FLAP may have other
activities in addition to leukotriene synthesis. To examine
this possibility and to define the role that FLAP plays in the
control of leukotriene synthesis during inflammatory re-
sponses in vivo, we generated FLAP-deficient mice, and
we compared the phenotype of these mice with that of
mice lacking the 5-LO enzyme.
 
Materials and Methods
 
Isolation of the Murine Flap Gene.
 
A 680-bp fragment of rat
 
Flap
 
 cDNA (17) was used as a probe to screen a genomic DNA
library in the Lambda FIX II vector generated from the 129
mouse strain (Stratagene Corp., La Jolla, CA). Five positive clones
were obtained. One of these genomic clones, 
 
Flap
 
 221, was iso-
lated and purified to homogeneity and the insert was subcloned
into the NotI site of pBluescript II SK
 
1
 
 (Stratagene Corp.). Re-
gions of the insert containing coding sequence were identified
and sequenced by the dideoxy chain termination method (U.S.
Biochemical, Cleveland, OH) to verify the identity of the clone and
to further localize regions containing coding sequence.
 
Generation of FLAP-deficient Mice.
 
A targeting vector for the
 
Flap
 
 gene was constructed from the murine genomic clone. Frag-
ments identical to their corresponding regions in the gene were
inserted 5
 
9
 
 and 3
 
9
 
 of the neomycin resistance gene (
 
neo
 
) of pJNS2
(36) such that coding material would be replaced by 
 
neo
 
 after ho-
mologous recombination of the plasmid with the endogenous lo-
cus. This construct was electroporated into E14TG2a embryonic
stem (ES) cells established from the 129/Ola mouse line (37), and
colonies resistant to neomycin and ganciclovir were identified as
described previously (36). Genomic DNA was isolated from dou-
bly resistant ES cell lines, digested with EcoRV and analyzed by
Southern blot using a 1.2-kb BamHI/NotI fragment downstream
of the targeting construct as a probe (Fig. 1 
 
A
 
). Verified recombi-
nant ES cell lines were microinjected into mouse blastocysts, and
chimeric mice were generated. Chimeras were bred to either
B6D2 or 129/SvEv mice, and offspring were genotyped by
Southern blot analysis of tail DNA digested with EcoRV using
the 1.2-kb probe described above. All animals used in our studies of
inflammation, with the exception of those assayed for platelet-acti-
vating factor (PAF) survival, were offspring of chimeras crossed
with 129/SvEv mice. Likewise, the 5-LO–deficient mice used as
controls for these experiments were on the 129 genetic back-
ground.
 
Measurement of Eicosanoid Production from Peritoneal Macrophages.
 
Macrophages were obtained by peritoneal lavage with 10 ml of
DME supplemented with 20 mM Hepes buffer 3 d after mice re-
ceived an intraperitoneal injection of 1 ml of 5% thioglycollate
medium. Cells were cultured in 1.5 ml DME for 30 min. Super-
natant was collected and replaced by medium containing A23187
Ca
 
2
 
1
 
 ionophore at 5 
 
m
 
g/ml for an additional 30 min. A23187 has
been shown to stimulate the release of eicosanoids from mac-
rophages (38). Supernatant was collected, and the number of cells
was verified by using a hexosaminidase assay, as is previously de-
scribed (39). Concentrations of LTC
 
4
 
, prostaglandin E
 
2
 
 (PGE
 
2
 
)
and thromboxane B
 
2
 
 (TXB
 
2
 
) in the pre- and poststimulation su-
pernatants were determined using enzyme immunoassay (EIA;
Cayman Chemical Co. Inc., Ann Arbor, MI). 
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Flap mRNA Analysis.
 
Macrophages from mice of the indi-
cated genotypes were isolated by peritoneal lavage as described
above. Total RNA was extracted from the cells using RNAzol B
(Tel-Test, Inc., Friendswood, TX) according to the protocol
supplied by the manufacturer and separated by gel electrophoresis
(15–20 
 
m
 
g/lane). Northern blot analysis was carried out accord-
ing to standard techniques using the 680-bp rat 
 
Flap
 
 cDNA (17)
as a probe to detect expression of 
 
Flap
 
 mRNA. A probe for rat
 
b
 
-
 
actin
 
 was used as a positive control. Densitometry was per-
formed to detect any changes in 
 
Flap
 
 expression (ImageQuaNT
v4.1 software; Molecular Dynamics, Sunnyvale, CA).
 
Inflammatory Responses Induced by AA.
 
129 strain 
 
Flap
 
 (
 
2
 
/
 
2
 
)
and (
 
1
 
/
 
1
 
) animals were injected intravenously with 0.5% Evans
blue dye (10 ml of dye solution/kg of body weight) dissolved in
PBS (2.7 mM KCl, 1.2 mM KH
 
2
 
PO
 
4
 
, 138 mM NaCl, 8.1 mM
Na
 
2
 
HPO
 
4
 
, pH 7.5) and filtered through a 0.2 
 
m
 
m nitrocellulose
membrane. The inside of the left ear was painted with 20 
 
m
 
l of
AA (100 mg/ml in acetone; Sigma Chemical Co., St. Louis,
MO) to induce an inflammatory response, while the right ear re-
ceived acetone alone on its inner surface. After a time period of
1–2.5 h for edema assays or 7 h for myeloperoxidase (MPO) anal-
ysis, mice were killed and an 8-mm-diam disc of tissue was ob-
tained from the center of each ear for analysis. For comparison,
experiments were carried out in parallel with 129 
 
5-lo
 
 (
 
2
 
/
 
2
 
)
mice.
 
Quantification of Edema and Vascular Permeability.
 
The wet weight
of each ear biopsy was determined to assess edema formation. Each
ear disc was then incubated in 1 ml of formamide at 55
 
8
 
C for 24 h.
Extravasation of Evans blue dye was quantified by spectrophoto-
metric analysis of the formamide extracts at 610 nm (40).
 
MPO Assay.
 
8-mm-diam ear punches were homogenized
and analyzed according to a protocol modified from Bradley et al.
(41) which has been previously described (42). Lysate MPO was
quantified by comparison to a standard curve derived from serial
dilution of MPO standard (Calbiochem Corp., San Diego, CA).
 
Zymosan A–induced Peritoneal Inflammation.
 
To induce perito-
neal inflammation in 
 
Flap
 
 (
 
2
 
/
 
2
 
), 
 
Flap
 
 (
 
1
 
/
 
1
 
), and 
 
5-lo
 
 (
 
2
 
/
 
2
 
)
animals, we used a protocol modified from Rao et al. (43). Zy-
mosan A (Sigma Chemical Co.) was dissolved in warm (56
 
8
 
C)
PBS (pH 7.5) to a final concentration of 1 mg/ml. The Zymosan
A solution was mixed until it passed freely through the 30-gauge
delivery needle. Each mouse received 1 ml Zymosan A solution
by intraperitoneal injection. After 3 h, mice were euthanized and
a peritoneal lavage was performed with 4 ml of ice-cold PBS.
The lavage fluid was collected, transferred to microcentrifuge
tubes, and centrifuged at 40,000 
 
g
 
 for 10 min. Supernatants were
collected and LTC
 
4
 
 levels were determined by EIA (Cayman
Chemical Co.). In related experiments, mice received 0.5% Evans
blue dye (10 ml of dye solution/kg of body weight) in PBS intra-
venously immediately before injection of Zymosan A solution.
Mice were euthanized after 10, 20, or 30 min and underwent
peritoneal lavage with 4 ml of cold PBS as described above. Evans
blue dye extravasation was assessed by light spectrophotometry at
610 nm.
 
Detection of 12–hydroxyeicosatetraenoic Acid Levels.
 
Peritoneal
inflammation was induced in FLAP-deficient and wild-type ani-
mals as described above. Lavage fluid was collected 30 min after
Zymosan A delivery and was centrifuged. 12-hydroxyeicosatet-
raenoic acid (HETE) levels in the supernatants were determined
by EIA (PerSeptive Diag., Framingham, MA).
 
Delayed-type Hypersensitivity Assay.
 
A method adapted from
that of Furue and Tamaki (44) was used to analyze the effect of leu-
kotriene deficiency on the development of a delayed-type hyper-
sensitivity (DTH) response. In brief, 129 strain 
 
Flap
 
 (
 
2
 
/
 
2
 
), 
 
5-lo
 
(
 
2
 
/
 
2
 
), and (
 
1
 
/
 
1
 
) mice homozygous for the 
 
p
 
 and 
 
c
 
ch
 
 alleles of
the 129/Ola line were sensitized by application of a 100 
 
m
 
l epicu-
taneous dose of 0.5% FITC (Sigma Chemical Co.) in 1:1 ace-
tone/dibutyl phthalate to the abdomen. After 6 d, the ears of each
animal were measured using calipers before eliciting a contact hy-
persensitivity reaction by topical application of 20 
 
m
 
l of 0.5%
FITC to the left ear. The right ear of each mouse received vehi-
cle alone. 24 h later, the ear thickness was again measured with
calipers. Mice were then killed, and ears were collected and
weighed as described above. Caliper measurements, as well as the
differences in wet weight between experimental (left) and control
(right) ears, were compared in mice of each genotype.
 
Passive Systemic IgE-induced Anaphylaxis. Passive systemic ana-
phylaxis was induced as previously described (36). Animals re-
ceived 20 mg of a monoclonal mouse anti–mouse DNP IgE in
200 ml of PBS intravenously. After 24 h, baseline body tempera-
tures were determined using a rectal probe, and mice received an
intravenous injection of 1 mg DNP–human serum albumin
(HSA) and 0.5% Evans blue in 200 ml PBS to induce anaphylaxis.
30 min after this injection, temperature changes were measured.
Mice were then killed, and edema was quantitated in 8-mm-diam
ear punches as described above.
PAF-induced Anaphylaxis. Mice received intravenous injec-
tions of 50 mg of PAF per kilogram of body weight in BSA at 2.5
mg/ml and propranolol at 0.05 mg/ml in saline. Survival was as-
sessed for 24 h after the injection of PAF.
Results
Generation of FLAP-deficient Mice. The  Flap targeting
vector was constructed using a clone isolated from a library
constructed with DNA from the 129 mouse strain (Fig. 1 A).
Fragments derived from the mouse Flap clone were used to
prepare a plasmid that, upon homologous recombination
with the endogenous locus, would result in the disruption
of the gene for this protein. The 800-bp XhoI/NheI frag-
ment, which is replaced by the neomycin resistance cassette
after homologous recombination (see Fig. 1 A), was sub-
cloned and sequenced. The sequence analysis showed that a
130-bp exon which encodes amino acids 108–151 is elimi-
nated in recombinant clones. These amino acids have been
shown to be highly conserved between several species
(86% identity with the human amino acid sequence), and
their removal would result in the loss of the third putative
transmembrane domain of the protein (18). Thus, even if
splicing around the missing exon were to take place, a large
and conserved portion of the transcript would be absent
and an inactive protein would likely result.
The JNS2/Flap1 plasmid was electroporated into
E14TG2a ES cells, and potential targeted clones were se-
lected by growth in the presence of G418 and ganciclovir.
Resistant colonies were picked, expanded, and screened for
homologous recombination by Southern blot analysis of
EcoRV digested genomic DNA using a 1.2-kb BamHI/NotI
probe downstream of the targeting construct (Fig. 1 A).
This probe hybridizes to a fragment of .16 kb from the
endogenous Flap locus, while introduction of a new EcoRV
site into the targeted locus results in a hybridizing fragment
of 8 kb (Fig. 1 B). A targeting frequency of 34% was ob-1068 Acute Inflammation in 5-Lipoxygenase–activating Protein–deficient Mice
served with the JNS2/Flap1 construct. Microinjection of
two verified recombinant ES cell lines, 160-9 and 160-37,
into mouse blastocysts yielded chimeric animals which
could transmit the recombinant Flap allele to their progeny.
Each of these cell lines gave rise to mice homozygous for
the Flap mutation in the F2 generation. Flap (2/2) mice
were present in the litters in expected numbers based on
Mendelian ratios for a heterozygous mating. This indicates
that disruption of the Flap gene had no effect on the fetal
survival or development of the animals. By simple observa-
tion, the FLAP-deficient mice were indistinguishable from
their Flap (1/2) and Flap (1/1) littermates.
To verify that the predicted coding sequence had been
deleted from the targeted Flap locus in these transgenic
mice, DNA samples from tail biopsies of Flap (2/2), Flap
(1/2), and Flap (1/1) mice were analyzed by Southern
blot, using the 800-bp XhoI/NheI fragment replaced by
neo in the recombinant locus. This probe hybridized to Flap
(1/1) and Flap (1/2) DNA, but showed no hybridiza-
tion to DNA from a Flap (2/2) animal, verifying the de-
letion of this critical coding region (data not shown).
Total RNA was isolated from peritoneal macrophages of
Flap (2/2), Flap (1/1), and 5-lo (2/2) mice. A North-
ern blot probed with the rat Flap cDNA (Fig. 1 C) shows
that the murine Flap mRNA is present in the Flap (1/1)
and 5-lo (2/2) lanes, but there is no hybridization in the
Flap ( 2 / 2 ) lanes. Because the full-length cDNA probe
contains sequences in addition to those eliminated by tar-
geting, these results support the interpretation that a critical
region of the Flap gene has been deleted through recombi-
nation and that there is no stable message being synthe-
sized.
Densitometry was performed on the autoradiograph in
Fig. 1 C. Comparison of the integrated areas of the Flap
mRNA bands relative to the levels of the b-actin mRNA
indicated only a slight elevation in Flap expression in mac-
rophages from 5-lo (2/2) mice. In the (1/1) sample, Flap
mRNA was 53.53% of b-actin mRNA levels which are an
indicator of the amount of RNA loaded in a given lane. In
the 5-lo (2/2) lane, Flap mRNA was 59.87% of b-actin
mRNA levels, or 1.12-fold of that measured in the wild
type. Thus, the absence of 5-LO results in little difference
in Flap expression.
Flap (2/2) Mice Do Not Produce Detectable Leuko-
trienes. Peritoneal macrophages collected from four Flap
(2/2) mice and from three (1/1) littermates were stimu-
lated with calcium ionophore to determine the ability of
these cells to release prostaglandins, thromboxanes, and leu-
kotrienes. After A23187 activation, a .200-fold increase in
LTC4 was detectable in supernatant from macrophages of
wild-type mice, while no LTC4 was detected in cells from
Flap (2/2) animals (Fig. 2 A). The ability of the FLAP-
deficient mice to produce prostaglandins and thrombox-
anes by the cyclooxygenase-dependent pathway remained
intact (Fig. 2, B and C). Similar to results obtained with
5-LO–deficient mice (42), levels of PGE2 and TXB2 that
were released from the Flap (2/2) macrophages after stim-
ulation were greater than those released from their (1/1)
counterparts. While both PGE2 and TXB2 production by
FLAP-deficient mice was increased compared to controls,
only the difference in prostaglandin production reached
statistical significance (P 5 0.028 and 0.078, respectively).
To determine whether a similar defect in leukotriene
synthesis occurred in vivo, an experimental peritonitis was
induced by the injection of Zymosan A into the peritoneal
cavity of Flap (2/2), 5-lo (2/2), and (1/1) mice. In
wild-type mice, Zymosan A induced a significant stimula-
tion of LTC4 (1,580 6 22 pg/ml). Consistent with the in
vitro data (Fig. 2 A), however, no LTC4 could be detected
in either Flap (2/2) or 5-lo (2/2) mice after Zymosan A
injection.
This question was further addressed in the accompanying
manuscript by performance of HPLC analysis of peritoneal
lavage fluids after Zymosan A stimulation of Flap (2/2)
and (1/1) animals on the DBA/1 lacJ genetic back-
ground. The chromatography verified that no leukotrienes
are being synthesized by FLAP-deficient animals. Further-
more, these profiles failed to detect an increase in other AA
metabolites of the 5-LO pathway (for example, 5-HETE
and the nonenzymatic hydrolysis products of LTA4) in the
Figure 1. Targeting of the Flap gene. (A) Partial restriction enzyme
maps of the targeting construct, the endogenous genomic clone, and the
recombinant locus. Coding sequences replaced by homologous recombi-
nation are indicated by the filled black box. The hsv-tk and NEO selec-
tion cassettes are indicated as hatched boxes (hsv, herpes simplex virus; tk,
thymidine kinase). Restriction enzyme sites are abbreviated: N, NotI; B,
BamHI; Nh, NheI; X, XhoI; R5, EcoRV; R, RmaI; H, HindIII. The
probe used to screen for homologous recombination by Southern blot
analysis is indicated by the filled gray box. (B) Southern blot analysis of
EcoRV-digested tail DNA from Flap (1/1), Flap (1/2), and Flap (2/2)
mice hybridized with a 1.2-kb BamHI/NotI fragment downstream of the
targeting construct’s region of homology. (C) Northern blot analysis of
total RNA isolated from peritoneal macrophages of Flap (1/1), Flap (2/2),
and 5-lo (2/2) mice hybridized with the rat FLAP cDNA. A rat b-actin
cDNA probe was used as a positive control.1069 Byrum et al.
absence of FLAP. Surprisingly, a significant decrease in
12-HETE, a product of the 12-LO pathway, was observed
in the DBA/1 lacJ Flap (2/2) mice. An z54% reduction
in 12-HETE compared to wild-type levels was verified in
these mutant mice by EIA. We have seen a similar trend in
an identical EIA for 12-HETE in 4 ml of stimulated perito-
neal lavage fluid from four Flap (2/2) and three (1/1)
mice on the 129 genetic background (50.25 ng/ml for
FLAP-deficient mice versus 82.16 ng/ml in their normal
controls). This reduction in 12-HETE levels, however, did
not achieve statistical significance.
Flap (2/2) Mice Exhibit Decreased Vascular and Cellular
Inflammatory Responses to AA. AA, when topically applied
to the skin of the murine ear, causes an intense acute in-
flammatory reaction with both vascular and cellular com-
ponents. Several lines of evidence support a role for
eicosanoids in this inflammation, including the recent dem-
onstration that this response is attenuated in 5-LO–defi-
cient and prostaglandin H2 synthase-1–deficient animals
(42, 45, 46). To examine the role of FLAP in the edema
and neutrophil recruitment characteristic of this response,
the ears of Flap (2/2) and control mice were treated with
2 mg of AA. The ears were later biopsied, and edema was
measured by determining the wet weight of each biopsy. In
conjunction with the measurement of edema, alteration in
plasma exudation was assessed using Evans blue dye. Since
Evans blue binds to serum proteins (40), quantification of
this dye in each ear biopsy gives a reliable indication of
changes in vascular permeability. Edema and vascular per-
meability in the Flap (2/2) mice were compared to wild-
type littermates.
As can be seen in Fig. 3 A, the increase in ear weight af-
ter AA treatment was significantly reduced in Flap (2/2)
mice compared to controls (P 5 8.9 3 1029). To deter-
mine whether the changes seen in the FLAP-negative ani-
mals were due solely to leukotriene deficiency, 5-lo (2/2)
mice were examined in the same way. As reported, the
AA-induced edema was significantly reduced in 5-lo (2/2)
animals compared to control mice (P 5 5.9 3 10216). Sur-
prisingly, however, the reduction in edema in the 5-lo (2/2)
was greater than that of the Flap ( 2 / 2 ) animals (P 5
0.001). The differences between these groups of mice were
replicated in at least two experiments performed on inde-
pendent days, with a total of 17 5-lo (2/2), 17 Flap (2/2),
and 38 (1/1) animals examined.
Changes in vascular permeability and extravasation of se-
rum proteins in response to topical AA followed a similar
pattern for mice of these three genotypes (Fig. 3 B). Ears of
wild-type mice displayed a deep blue color after topical AA
treatment, reflecting leakage of serum proteins into the in-
terstitial space, while Flap ( 2 / 2 ) mice and 5-lo ( 2 / 2 )
mice showed a lighter blue color by observation and after
quantitation (P 5 1.7 3 1027 and 3.5 3 10212, respec-
tively). Again, the loss of 5-lo gene function had a greater
impact on edema formation than did the disruption of the
gene for FLAP, and this relationship was consistent in at
least two experiments performed on separate days with a
total of 16 5-lo (2/2), 17 Flap (2/2), and 38 (1/1) ani-
Figure 2. Ca21 ionophore–induced eicosanoid production in Flap (1/1)
and Flap (2/2) mice. Peritoneal macrophages from three Flap (1/1)
and four Flap (2/2) mice were cultured in 1.5 ml tissue culture medium
for 30 min. Medium was collected and replaced with medium containing
Ca21 ionophore A23187 (5 mg/ml). Supernatant was again collected 30
min after stimulation. LTC4 (A), PGE2 (B) and TXB2 (C) levels in the
prestimulation (solid bars) and poststimulation (hatched bars) supernatants
were determined by EIA. After ionophore stimulation and supernatant
collection, the number of adherent macrophages was determined by using
a hexosaminidase assay. Eicosanoid levels were then normalized to reflect
106 macrophages. Error bars indicate SEM.1070 Acute Inflammation in 5-Lipoxygenase–activating Protein–deficient Mice
mals. The difference between the two experimental groups
was not as pronounced, however, as the difference in their
ear weight described above (P 5 0.0445).
In addition to their roles in edema formation and vascular
changes, the leukotrienes are important in the establishment
and maintenance of the cellular response to acute injury.
LTB4 exerts a potent chemotactic effect upon neutrophils,
causing the adhesion of PMN to vascular endothelia and
extravasation into the tissues in the acute inflammatory re-
sponse. We therefore examined the ability of FLAP to af-
fect the cellular infiltration elicited by topical AA. Levels of
MPO, an enzyme specific for neutrophils, can be used as an
indicator of the number of PMN present in inflamed tissue
(38). The MPO level for experimental and control ears of
mice of each genotype was determined by enzymatic assay
7 h after the topical AA treatment. The MPO content of
unstimulated ears was uniformly undetectable by our assay
for all mice tested. After AA stimulation, ear biopsies ex-
hibited MPO activity, reflecting the recruitment of neutro-
phils to the treated tissue. Mean MPO activity for twelve
129 strain (1/1), six Flap (2/2), and five 5-lo (2/2)
mice is shown in Fig. 3 C. Neutrophil infiltrate was signif-
icantly decreased in the Flap (2/2) and 5-lo (2/2) ani-
mals compared to the wild-type controls (P 5 1025 and 7 3
1026 respectively). These results were obtained in two separate
experiments. In contrast to the assays of edema and vascular
leakage, we observed no difference in MPO levels between
FLAP– and 5-LO–deficient mice. Thus, in the Flap (2/2)
animals we attribute reduction in recruitment of PMN to
the inability of these mice to produce leukotrienes.
Figure 3. Acute inflammatory response to topical arachidonic acid in
Flap (2/2), 5-lo (2/2), and (1/1) animals. Arachidonic acid (2 mg) in
acetone was applied to the left ear and acetone alone to the right ear of
experimental mice. Flap (2/2) animals are indicated by hatched shading,
5-lo (2/2) by grey shading, and (1/1) by solid shading. Mice analyzed
for edema and plasma protein extravasation received 0.5% Evans blue dye
intravenously and were killed after 1 h, whereas mice tested for neutro-
phil infiltration were killed after 7 h. 8-mm-diam discs were cut from
each ear for analysis. (A) The wet weight difference between the treated
and untreated ears of each animal was recorded as an indicator of tissue
edema. n 5 17 Flap (2/2), 17 5-lo (2/2), and 38 (1/1) mice. (B) Ex-
travasation of plasma proteins into tissue was quantitated by extraction of
dye with formamide and spectrophotometric analysis of extracts at 610
nm. The difference between the A610 for the left and right ears of each
mouse was recorded. n 5 17 Flap (2/2), 16 5-lo (2/2), and 38 (1/1)
mice. (C) Neutrophil infiltration was assessed by measuring differences in
MPO activity in lysates of experimental and control ear biopsies. MPO
activity was determined by comparison with a standard curve of quanti-
fied MPO in an enzymatic assay. n 5 6 Flap (2/2), 5 5-lo (2/2), and 12
(1/1) mice. Error bars indicate SEM.
Figure 4. Leukotriene production and acute inflammation in experi-
mental peritonitis. FLAP-deficient (circles), 5-LO–deficient (triangles), and
wild-type (squares) mice received an intraperitoneal injection of 1 ml Zy-
mosan A in PBS (1 mg/ml) to elicit peritoneal inflammation. To measure
plasma protein influx, mice received 0.5% Evans blue dye intravenously
before Zymosan A treatment. Mice were killed at time points of 10, 20,
and 30 min, and peritoneal lavage was performed with 4 ml PBS. Cells
were removed by centrifugation, and wash fluid was analyzed for Evans
blue dye extravasation by light spectrophotometry at 610 nm. n 5 3–8
mice at 0 min, 4–11 mice at 10 min, 5–10 mice at 20 min, and 4–11 mice
at 30 min. Error bars indicate SEM.1071 Byrum et al.
Leukotriene-dependent Edema of Induced Peritonitis is Absent
in Flap (2/2) Mice. To further explore the roles of FLAP,
5-LO, and leukotrienes in inflammatory edema, we evalu-
ated plasma protein extravasation in response to another in-
jurious stimulus, Zymosan A treatment. Peritoneal lavage
was performed at 0, 10, 20, and 30 min time points, and
the wash fluid was analyzed for Evans blue. As shown in
Fig. 4, the absence of FLAP and 5-LO had similar effects
on Evans blue extravasation after Zymosan A exposure. In
two independent experiments, no difference was observed
in the degree of inhibition conferred by FLAP or 5-LO de-
ficiency.
Flap (2/2) Mice Exhibit a Normal DTH Response.
Contact hypersensitivity to FITC is a form of DTH in-
duced by topical application of antigen. It is initiated by
T cells and can be quantitated by challenging the ears of
sensitized animals and then measuring the swelling of the
tissue after 24 h. Previous reports have suggested that leu-
kotrienes may affect T cell cytokine production in vivo
(47, 48). Production of leukotrienes by myeloid cells acti-
vated in this inflammatory response are likely to contribute
further to the pathological changes of the DTH response.
To examine a possible role for FLAP and/or leukotrienes
in the DTH response, the ability of five Flap (2/2) and
five 5-lo (2/2) mice to mount a DTH response to cutane-
ous FITC in acetone/dibutyl phthalate was compared to
that of nine wild-type animals. In wild-type mice, ear weight
increased (14.12 6 2.8 mg) after FITC challenge. Both
FLAP– and 5-LO–deficient mice tended to exhibit a
smaller increase in ear edema after similar treatment (Fig. 5).
The differences between the three groups of mice, how-
ever, do not achieve statistical significance. FLAP-deficient
animals showed a mean D ear weight of 10.42 6 2.16 mg
after treatment, whereas 5-LO–deficient mice had a D ear
weight of 10.62 6 2.93 mg (P 5 0.16 and 0.23, respec-
tively).
Flap (2/2) Mice Show Edema Formation and Temperature
Change in a Passive Systemic IgE-dependent Anaphylaxis.
Systemic IgE anaphylaxis in the mouse is characterized by
bronchconstriction, plasma extravasation, hypotension with
resultant tachycardia, and drop in body temperature. In the
passive IgE-induced anaphylaxis model, these changes are
dependent on binding of IgE to the high affinity IgE recep-
tor, followed by mast cell degranulation (36). Leukotrienes,
which are not stored in granules but are synthesized when
the cells are activated, are among several proinflammatory
mediators released by stimulated mast cells that can contrib-
Figure 5. DTH reaction in Flap (2/2), 5-lo (2/2), and (1/1) mice.
Animals were sensitized with a 100 ml epicutaneous dose of 0.5% FITC in
1:1 acetone/dibutyl phthalate to the shaved abdomen. After 6 d, a hyper-
sensitivity response was elicited by topical application of 20 ml of an iden-
tical FITC solution to the left ear. The right ear of each mouse received
vehicle alone. 24 h later mice were killed, and 8-mm-diam discs were iso-
lated from each ear. Wet weight differences between the left and right
ears of each mouse were recorded as indicators of a DTH response. Flap
(2/2) animals are indicated by hatched shading, 5-lo (2/2) by grey
shading, and (1/1) by solid shading. n 5 five Flap (2/2), five 5-lo
(2/2), and nine (1/1) mice. Error bars indicate SEM.
Figure 6. Passive systemic IgE-induced anaphylaxis. Flap (2/2) and
(1/1) mice received 20 mg of a monoclonal mouse anti–mouse DNP
IgE in 200 ml PBS intravenously. 24 h later basal body temperatures were
recorded, and mice received an intravenous injection of 1 mg DNP-HSA
and 0.5% Evans blue dye in 200 ml PBS to induce mast cell degranulation
and anaphylaxis. Basal body temperature was again recorded 30 min after
this injection. (A) Animals of the indicated genotypes were killed and
8-mm-diam ear discs were isolated. Extravasation of plasma proteins into
tissue was quantitated by extraction of dye with formamide and spectro-
photometric analysis of extracts at 610 nm. Dye leakage into both the left
and right ears was recorded in this systemic response. (B) Change in basal
body temperature for Flap (2/2) and (1/1) mice 30 min after treatment
was recorded as another measure of systemic anaphylaxis. n 5 five Flap
(2/2) and four (1/1) mice. Error bars indicate SEM.1072 Acute Inflammation in 5-Lipoxygenase–activating Protein–deficient Mice
ute to these physiological effects. To test the role of FLAP
in the anaphylactic response, IgE-dependent passive sys-
temic anaphylaxis was induced in five FLAP-deficient and
four control mice. Mast cells of the animals were loaded
with a monoclonal mouse anti–mouse DNP IgE. 24 h later
DNP-HSA and Evans blue were administered. Body tem-
perature was taken using a rectal probe before and 30 min
after the DNP-HSA treatment. Finally, mice were killed,
and edema was quantitated by measuring the amount of
Evans blue dye in 8-mm-diam ear biopsies. Flap (2/2)
mice averaged a 3.76 6 0.358C drop in body temperature
after the induction of passive anaphylaxis that was less ex-
treme than the 4.98 6 1.048C drop seen in the (1/1)
mice (Fig. 6 A). This reduced response, however, was not
statistically significant (P 5 0.174). Likewise, the A610 of
ear extracts from each group showed similar levels of Evans
blue dye extravasation (Fig. 6 B). The mean A610 of extracts
from the ears of FLAP-deficient mice was 0.1006 6
0.0057. Wild-type mice edema levels reached A610 5
0.0859  6 0.0082, which again indicates no significant dif-
ference between Flap ( 2 / 2 ) and (1/1) animals (P 5
0.075). Analogous results have been seen on examination
of the 5-LO–deficient mice (data not shown).
Flap (2/2) Mice Are Resistant to PAF-induced Anaphy-
laxis. PAF is a potent endogenous mediator of inflamma-
tory systemic anaphylaxis and shock, causing microvascular
leakage, vasodilation, contraction of smooth muscle, endo-
thelial adhesion, and activation of neutrophils, macro-
phages, and eosinophils. It is thought that many of the
physiological changes that result from intravenous doses of
PAF could be brought about by the PAF-mediated release
of leukotrienes (42, 45, 49–52). Vulnerability of FLAP-defi-
cient mice and their wild-type littermates to PAF-induced
anaphalaxis was determined by treating 12 Flap (2/2) and 8
(1/1) animals with intravenous PAF. 75% (9 of 12) of Flap
(2/2) animals survived this treatment, compared to only
12.5% (1 of 8) of the control group. Analysis of these re-
sults using the x2 test indicates a difference in susceptibility
to PAF-induced anaphylaxis between the Flap (2/2) and
(1/1) groups with a significance level of 0.0062. This dif-
ference is similar to that seen between the 5-LO–deficient
and wild-type mice, as reported previously (42, 45). The
protection from anaphylactic shock conferred by FLAP or
5-LO deficiency suggests a crucial role for leukotrienes in
this process. While other inflammatory mediators are in-
volved in the systemic anaphylactic response, none are able
to compensate for the absence of the leukotrienes.
Discussion
FLAP was discovered by the identification of targets for
agents that block leukotriene synthesis but have no effect
on 5-LO enzyme activity (22). The protein has been shown
to possess significant structural homology with LTC4 syn-
thase, another enzyme involved in the leukotriene syn-
thetic pathway. In particular, the region of FLAP that is
critical for the action of the inhibitory drug MK-886 is
conserved in LTC4 synthase, suggesting that the two pro-
teins may also share some functional homology (19). Here
we characterized the role of FLAP by examining the in-
flammatory responses of mice that are homozygous for a
mutant allele of the Flap gene. To determine whether alter-
ations in these responses are due solely to FLAP’s facilita-
tion of leukotriene synthesis, parallel experiments were
performed with mice carrying a mutation in the 5-lo gene.
These mice, like the FLAP-deficient animals, were gener-
ated by introducing mutations into the genome of embry-
onic stem cells by homologous recombination (42).
No difference was observed in the ability of mice lacking
FLAP to survive, nor was any alteration in the develop-
ment of the various populations of myeloid and lymphoid
cells apparent. An essential role for FLAP in the production
of leukotrienes was suggested by in vitro studies and by
work using drugs that were shown to bind specifically to
FLAP (17, 22, 23). Here we show that leukotriene synthe-
sis is undetectable in cells or whole animals that fail to ex-
press FLAP. This confirms the requirement of functional
FLAP for normal production of leukotrienes. Also, the lack
of leukotriene production in these mice indicates that the
newly isolated 30-kD FLAP-2 (20), which shows homol-
ogy to both FLAP and LTC4 synthase, is not a functional
complement of FLAP in AA metabolism. In addition, FLAP-
deficient mice showed slight decreases in 12-HETE pro-
duction in response to Zymosan A stimulus. Although we
did not see a statistically significant difference in our exper-
iments, examination of a larger group of mice in the ac-
companying paper confirmed this observation. It is possible,
therefore, that whereas not absolutely required, FLAP facil-
itates the production of 12-HETE in the 12-LO pathway.
To further define the role of leukotrienes in acute in-
flammatory processes and to continue our exploration of
potential additional functions for FLAP, we analyzed FLAP–
and 5-LO–deficient mice in a number of experimental
models of inflammation. We initially focused on vascular and
cellular changes after topical AA administration. Attenua-
tion of this response has been reported previously in mice de-
ficient in the 5-LO protein (42, 45). In our own early stud-
ies, we found that edema was decreased in 5-LO–deficient
mice, but the difference was not statistically significant.
Much of the difficulty in achieving statistically significant
differences between the two groups of animals stemmed
from the considerable variability in the responses of both
wild-type and 5-LO–deficient mice to AA. We reasoned
that the inflammatory responses in these mice, which were
129 and B6D2 F2 offspring, were influenced by genetic
factors in addition to the 5-lo gene. To examine the roles of
FLAP and 5-LO independent of these factors, the in vivo
experiments described in this report (with the exception of
PAF-induced anaphylaxis) were carried out on mice in which
the mutated 5-lo and Flap genes were maintained on the
129 background by breeding the chimeric animals (gener-
ated from 129/Ola ES cells) to 129/SvEv mice. When back-
ground variability was eliminated, a statistically significant
reduction in mean edema was achieved between the 5-LO–
deficient and control groups.1073 Byrum et al.
The edema and increased vasopermeability characteristic
of AA-induced ear inflammation were reduced in the
FLAP-deficient mice relative to control animals, but each
remained significantly higher than that of the 5-LO–defi-
cient animals. This was, notably, the only assay in which a
reproducible and consistent difference was seen between
the 5-LO– and FLAP–deficient mice. Even in this inflam-
matory response, significant differences were seen between
these two groups only when inflammation was assessed by
measuring changes in the weight of a constant area of tis-
sue. Smaller changes were observed on evaluation of va-
sopermeability and cellular inflammation. One possible ex-
planation for the difference in response between mice
lacking 5-LO and FLAP in this particular assay may be that,
in some circumstances of extremely high AA substrate, for-
mation of leukotrienes is possible without the association of
the enzyme with FLAP (17). This would be compatible
with the finding that in vitro formation of leukotrienes
from AA is possible in the absence of FLAP. Experiments
that have examined the dependence of leukotriene synthe-
sis on FLAP have shown that leukotriene production is
stimulated by the treatment of cells with ionophore. Con-
sistent with the results obtained here by stimulating FLAP-
deficient peritoneal macrophages, leukotriene synthesis was
found to be inhibited by drugs that interfere with the func-
tion of FLAP (23, 53). These results and our finding that
FLAP-deficient mice show some response to topical AA
support the theory that, under unique conditions of high
substrate availability, production of leukotrienes is possible
in the absence of FLAP. It is not clear why the positive re-
sponse of the FLAP-deficient mice to AA was most appar-
ent in measurements of ear weight edema and (to a lesser
extent) vascular permeability, whereas levels of cellular in-
filtration in similarly treated ears were equivalent in the
FLAP– and 5-LO–deficient mice. One possible explana-
tion for these results is that the enzymes that carry out sub-
sequent metabolism of LTA4 differ depending on the intra-
cellular localization of the 5-LO enzyme. Metabolism of
AA in the absence of FLAP may occur at intracellular sites
other than the nuclear envelope, where 5-LO and FLAP
normally interact. The production of LTA4 at a different
intracellular location could alter its availability to LTA4 hy-
drolase and LTC4 synthase and, in turn, affect the ratio of
LTB4 to LTC4 production in FLAP-deficient cells. Because
LTB4 and LTC4 differ in their contributions to vascular and
cellular events during inflammation, changes in the pro-
duction of these two leukotrienes in the FLAP-deficient
mice could explain the results we see in the edema/plasma
extravasation and neutrophil infiltration assays.
Edema formation is also characteristic of the acute in-
flammatory response seen in IgE-mediated anaphylaxis.
The absence of observable differences in edema or vasoper-
meability between FLAP-deficient mice, 5-LO–deficient
mice, and normal controls in these experiments is not sur-
prising given the complexity of this response. In contrast
with the relatively straightforward stimulation of a single
metabolic pathway by topical AA, a wide variety of media-
tors that can lead to inflammatory changes similar to those
induced by leukotrienes are produced in IgE-mediated
anaphylaxis. It is likely that the release of other mediators
such as histamine, a potent vasoactive substance, plays a key
role. Although no differences were observed between FLAP-
deficient and control mice here, under physiological condi-
tions in which IgE receptors are not completely occupied
or antigen is limited such that few mast cells are activated,
the absence of leukotrienes may possibly have an impact on
the extent of the edema formation.
The lack of FLAP and leukotrienes also failed to result in
detectable attenuation of the contact hypersensitivity in-
duced by FITC. Past reports suggested that leukotrienes
may influence T cell–mediated responses at a number of
levels. LTB4 has been shown to alter IFN-g, IL-2, and IL-1
production by T cells and monocytes (47, 48, 54). In addi-
tion, leukotrienes may contribute to this inflammatory pro-
cess indirectly since they are likely to be produced by the
myeloid cells recruited to sites of inflammation. Our failure
to see a difference in this response may again reflect the
complexity of the process. Numerous pathways may exist
for eliciting the physiological changes that have been ob-
served, and, whereas leukotrienes may contribute to such
changes, other mediators may mask their deficiency. It
could be that lower levels of stimulation would allow us to
observe a more subtle change in this response. Such a situa-
tion has been described in an analysis of trinitrochloroben-
zene-mediated contact hypersensitivity in IL-1–deficient
mice (55). In this case, response variation in mutant mice
was apparent only at low antigen concentrations.
In both the 5-LO– and the FLAP–deficient mice, strik-
ing alterations were seen in the kinetics of peritoneal
edema formation after the injection of Zymosan A. Zymo-
san A can induce an inflammatory response through a
number of pathways including activation of alternate path-
way of complement, the generation of anaphylatoxins, and
the activation of mast cells and basophils. The response is
also characterized by the biosynthesis of arachidonic acid
metabolites and by neutrophil and macrophage phagocyto-
sis (43). Examination of the edema formation in the 5-LO–
and FLAP–deficient mice shows that leukotrienes are es-
sential mediators of the early reaction to this stimulus. Again,
the similar responses seen in the FLAP– and the 5-LO–
deficient mice suggest that FLAP has no additional role in
inflammation beyond its absolute requirement for leuko-
triene synthesis.
In conclusion, we have used a genetic approach to show
that mice made deficient in FLAP survive and breed nor-
mally but are generally unable to metabolize AA to leuko-
triene products. Further, we show that the absence of
FLAP reduces the inflammatory response in a subset of
model systems. The mice lacking FLAP, along with a
growing number of other animals deficient in immunologi-
cally important genes, should eventually allow specific cel-
lular and molecular dissection of the biochemical pathways
leading to inflammatory pathologies.1074 Acute Inflammation in 5-Lipoxygenase–activating Protein–deficient Mice
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